Intravenous to oral conversion of antihypertensives: A toolkit for guideline development

Annals of Pharmacotherapy

Volumn 44, Issue 9, 2010, Pages 1430-1447

  Dasta, Joseph F ^a,b   Boucher, Bradley A ^c   Brophy, Gretchen M ^d   Cohen, Henry ^e,f   Hassan, Erkan ^g,h   MacLaren, Robert ⁱ   Muzykovsky, Karina ^f   Martin, Steven J ^j   Pass, Steven E ^k   Seybert, Amy L ^l,m  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e LONG ISLAND UNIVERSITY   (United States)

^f KINGSBROOK JEWISH MEDICAL CENTER   (United States)

^g PHILIPS HEALTHCARE   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j UNIVERSITY OF TOLEDO   (United States)

^k TEXAS TECH UNIVERSITY   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

Acute hypertension; Hypertensive crisis; Oral conversion program; Oral transition program

Indexed keywords

CANDESARTAN; CAPTOPRIL; CLEVIDIPINE; ENALAPRIL; ENALAPRILAT; EPROSARTAN; ESMOLOL; FENOLDOPAM; FOSINOPRIL; GLYCERYL TRINITRATE; GUANABENZ; GUANFACINE; HYDRALAZINE; IRBESARTAN; LABETALOL; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; MOEXIPRIL; NICARDIPINE; NITROPRUSSIDE SODIUM; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANOREXIA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONSTIPATION; COUGHING; CYANIDE TOXICITY; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG METABOLISM; DYSPNEA; FATIGUE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FLUSHING; FOOD; GASTROINTESTINAL ABSORPTION; HEADACHE; HEADACHE AND FACIAL PAIN; HEALTH CARE SYSTEM; HEART PALPITATION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFORMATION; INFUSION PUMP; INJURY; LITERATURE; MEAN ARTERIAL PRESSURE; METHEMOGLOBINEMIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; SYNCOPE; TABLET; TACHYCARDIA; THIOCYANATE TOXICITY; THROMBOPHLEBITIS; VOMITING;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; INPATIENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 77956237270     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P086     Document Type: Review

References (69)

1. Dasta J, Kim SR, McLaughlin TP, Mody S, Piech CT. Incremental daily cost of mechanical ventilation in patients receiving treatment in an intensive care unit. Crit Care Med 2005;33:1266-71. (Pubitemid 40827376)
2. Dasta JF, Durtschi AJ, Kane-Gill SL. Pharmacoeconomics. In: Grenvik, A, ed. Critical care. Textbook of critical care. 5th ed. Philadelphia, PA: Elsevier Saunders, 2005:1732-9.
3. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia. Drugs 2008;68:2469-81.
4. Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications. Arch Intern Med 2003;163:2585-9.
5. Katz JN, Gore JM, Amin A, et al., on behalf of the STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: results from the Studying the Treatment of Acute hyperTension Registry. Am Heart J 2009;158:599-606.
6. Benson J, Gerlach A, Dasta J. National survey of acute hypertension management. Crit Care Shock 2008;11:154-66.
7. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke 2007;38:1655-711.
8. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007;38:2001-23.
9. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
10. Rhoney D, Peacock F. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm 2009;66:1343-52.
11. Rhoney D, Peacock F. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm 2009;66:1448-57.
12. Quershi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008;118:176-87.
13. Varon J. Treatment of acute severe hypertension. Drugs 2008;68:283-97.
14. Curran MP, Robinson DM, Keating GM. Intravenous nicardipine. Drugs 2006;66:1755-82.
15. Anadu U, Erowele GI, Ebiasah R, Green W. Clevidipine: a new intravenous option for the management of acute hypertension. Am J Health Syst Pharm 2010;67:351-60.
16. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-70.
17. Banco H, Goldwater SH, Adams E. Smoothing the path for intravenous to oral conversion: where have we come in 11 years? Hosp Pharm 2009;44:959-67.
18. Martin SJ, Close SJ. Fluoroquinolone-associated length of stay reduction in the hospital treatment of community-acquired pneumonia. Infect Dis Clin Pract 2003;11:540-9.
19. Lexi-Comp. Hudson, OH (accessed 2009 Sept 29).
20. AHFS essentials. Lexi-Comp Online. http://www.crlonline.com/crlsql/ servlet/crlonline (accessed 2009 Nov 11).
21. Thomson Micromedex. http://www.micromedex.com/cust-center/cs-uspup.htm (accessed 2009 Nov 11).
22. Product information. Labetalol. Bedford, OH: Bedford Laboratories, June 2000.
23. Product information. Metoprolol. Irvine, CA: Teva Parenteral Medicines, Inc., June 2007.
24. Product information. Esmolol. Irvine, CA: Teva Parenteral Medicines, Inc., June 2007.
25. Product information. Cardene (nicardipine). Deerfield, IL: Baxter Healthcare Corporation, November 2008.
26. Graham DJM, Dow RJ, Hall DJ, Alexander F, Mroszczak EJ, Freedman D. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 1985;20:23S-8S.
27. Product information. Cleviprex (clevidipine). Parsippany, NJ: The Medicines Company, August 2008.
28. Product information. Enalaprilat. Bedford, OH: Bedford Laboratories, June 2005.
29. Product information. Hydralazine. Shirley, NY: American Regent, Inc., January 2009.
30. Product information. Nitroglycerin. Irvine, CA: Teva Parenteral Medicines, Inc., June 2007.
31. Product information. Nitroprusside. Lake Forest, IL: Hospira, Inc., October 2007.
32. Product information. Fenoldopam. Bedford, OH: Bedford Laboratories, August 2004.
33. Cohen H, Alafris A, Levy SB. Drugs affecting circulation: antihypertensives, antianginals, antithrombotics. In: Gardenhire DS, ed. Respiratory care pharmacology. 7th ed. Mosby Publishers, St. Louis, MO 2008:386-416.
34. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: seventh report of the Joint Committee on detection, evaluation and treatment of high blood pressure [JNC-VII]. Hypertension 42:1206,2003.
35. Hamblin S, Furmanek D, Cass A. Optimal methods of transitioning from intravenous to oral antihypertensives: a pilot study (abstract 878). Crit Care Med 2009;37:A430.
36. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255-71.
37. Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet 2008;47:449-62.
38. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm 2008;65:2347-57.
39. Magnuson BL, Clifford TM, Hoskins LA, Bernard AC. Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract 2005;20:618-24.
40. Dickerson RN, Tidwell AC, Brown RO. Adverse effects from inappropriate medication administration via a jejunostomy feeding tube. Nutr Clin Pract 2003;18:402-5.
41. Phillips NM, Nat R. A systematic review of nursing administration of medication via enteral tubes in adults. J Clin Nurs 2008;17:2257-65.
42. Micromedex 1.0 Healthcare Series. Greenwood Village, CO: Thomson Reuters Healthcare Inc. (accessed 2009 Nov 11).
43. Vogel F. Intravenous/oral sequential therapy in patients hospitalized with community-acquired pneumonia: which patients, when and what agents? Drugs 2002;62:309-17. (Pubitemid 34169436)
44. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008;143:1098-105.
45. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005;48:1114-25.
46. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728-35.
47. Buchler MW, Seiler CM, Monson JRT, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol 2008;28:312-5.
48. McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009;33:277-316.
49. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease co-morbidities in 2003-2004. Arch Intern Med 2007;167:2431-6.
50. Ludden TM, Shepherd AM, McNay JL, et al. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther 1980;28:736-42.
51. Kramer AH, Bleck TP. Acute hypertension management in the ICU. In: Gabrielli A, Layon AJ, Yu M, eds. Critical care. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2009:1887-98.
52. Halaszynski TM, Juda R, Silverman DG. Optimizing postoperative outcomes with efficient preoperative assessment and management. Crit Care Med 2004;32:S76-86.
53. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG. Blood pressure and clinical outcomes in the international stroke trial. Stroke 2002; 33:1315-20. (Pubitemid 34517053)
54. Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomized, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009;8:48-56.
55. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-703.
56. Eveson DJ, Robinson TG, Potter JF. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens 2007;20:270-7.
57. Thomas D, Bath PM, Lees K, et al., for the ENOS Trial Investigators. Glyceryl trinitrate vs control, and continuing vs stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the efficacy of nitric oxide in stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 2006;1:245-9.
58. COSSACS Trial Group. COSSACS (Continue or Stop post-Stroke Antihypertensives Collaborative Study): rationale and design. J Hypertens 2005;23:455-8.
59. Papademetriou V, Farsang C, Elmfeldt D, et al., for the SCOPE Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175-80.
60. PROGRESS Collaborative group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
61. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
62. Jamerson K, Weber MA, Bakris GL, et al., for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
63. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
64. Goldwater SH, Heal-Janifer A, Milkovich G, Chatelain F. Smoothing the path for IV-to-oral conversion. Am J Health Syst Pharm 1997;54:200-5.
65. Wong-Beringer A, Nguyen K-H, Razeghi J. Implementing a program for switching from IV to oral antimicrobial therapy. Am J Health Syst Pharm 2001;58:1146-9. (Pubitemid 32552901)
66. Zamin MT, Pitre MM, Conly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother 1997;31:564-70.
67. Ehrenkranz NJ, Nerenberg DE, Shultz JM, Slater KC. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening of stay. Infect Control Hosp Epidemiol 1992;13:21-5.
68. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997;17:271-6.
69. Roberts BL. Decentralizing an IV to oral conversion program. Am J Hosp Pharm 1997;54:524-5.